Time Pas­sages: Bruce Gold­smith out at Jim Wilson's gene ther­a­py biotech; Flag­ship re­veals Michael Sev­eri­no’s CEO gig

→ When Pas­sage Bio read­just­ed its pipeline pri­or­i­ties, pruned its work­force by 13% and saw its R&D chief Eliseo Sali­nas walk out in March, it would be nat­ur­al to as­sume that this con­flu­ence of events could lead to more im­mi­nent changes. This week, CEO Bruce Gold­smith fol­lowed Sali­nas and board mem­ber Liam Rat­cliffe out the door.

Pas­sage Bio and Gold­smith both felt it was in their best in­ter­ests to move on as the Jim Wil­son biotech shifts its fo­cus to GM1 gan­gliosi­do­sis, Krabbe dis­ease and fron­totem­po­ral de­men­tia. Gen­er­al coun­sel and cor­po­rate sec­re­tary Edgar “Chip” Cale has been named in­ter­im chief as the search gets un­der­way for Gold­smith’s re­place­ment, hav­ing leaped to Pas­sage Bio in 2019 af­ter a 21-year ca­reer at GSK that con­clud­ed as SVP, le­gal cor­po­rate projects. Gold­smith left Deer­field to suc­ceed co-founder Stephen Squin­to as Pas­sage Bio’s CEO in ear­ly 2020.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN